Other

Incyte·Balance Sheet Statement·27 metrics

Breakdown

Metric	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Cumulative Cost Basis	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.2B	$1.1B	$1.1B
Accounts Receivable, after Allowance for Credit Loss	$739.1M	$758.5M	$853.2M	$823.1M	$842.9M	$895.9M	$1B	$1.1B
Provision for contract loss	$349.9M	$381.7M	$438.1M	$467.8M	$542M	$599.9M	$642.5M	$722.4M
Investments	—	—	$469.9M	$465.7M	$465.5M	$473.1M	$480.8M	$555.2M
Estimated Fair Value	—	—	—	$466.9M	$466.8M	$474.8M	—	$554.7M
Inventory Net Current and Noncurrent	$356M	$368.4M	$407.2M	$429.3M	$451.5M	$450M	$443.3M	$447M
Common stock, shares authorized (in shares)	$400M	$400M	$400M	$400M	$400M	$400M	$400M	$400M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	—	—	—	$210M	$245.4M	$297.1M	—	$337.7M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	—	—	—	$256.9M	$221.4M	$177.8M	—	$217.1M
Common stock, shares issued (in shares)	$191.6M	$192.8M	$193.4M	$193.8M	$194.1M	$196.1M	$198.5M	$199.9M
Common Stock, Shares, Outstanding	$191.6M	$192.8M	$193.4M	$193.8M	$194.1M	$196.1M	$198.5M	$199.9M
Clinical related costs	$105.7M	$120.6M	$132.4M	$132.7M	$146.3M	$157.7M	$175.9M	$177.7M
Inventory incurred prior to FDA approval	$34.9M	$32.3M	—	$27.7M	$47.4M	$45.4M	—	$40.9M
Licensing Arrangements	$444.3M	$491.1M	$519.9M	$549.2M	$33.1M	$36.9M	$40.7M	$37.5M
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$25.5M	$25.1M	$30.8M	$29.9M	$29M	$28.2M	$27.5M	$26.7M
Expected Pension Contributions	$10M	$10M	—	$10.1M	$10.1M	$10.1M	—	$12.6M
Defined Benefit Plan Expected Future Employer Contributions Current Fiscal Year	$10M	$10M	—	$10.1M	$10.1M	$10.1M	—	$12.6M
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number	$7.1M	$8.7M	$8.7M	$8.5M	$8.5M	$9.9M	$9.3M	$9.1M
Incentive stock program, shares reserved for future grants (in shares)	$10.7M	$4M	$4M	$3.2M	$11.8M	$8.9M	$9.1M	$8.8M
Preferred Stock, Shares Authorized	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$5M
Current maturities of long-term debt	$3.9M	$3.9M	$4.4M	$4.5M	$4.5M	$4.5M	$4.5M	$4.4M
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	—	$67.8	$67.8	$67.2	$67.7	$66.6	$66.9	$67.9
Common stock, par value (in dollars per share)	$0	$0	$0	$0	$0	$0	$0	$0
Preferred Stock, Par or Stated Value Per Share	$0	$0	$0	$0	$0	$0	$0	$0
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0	$0	$0	$0	$0	$0	$0	$0
Preferred Stock, Shares Issued	$0	$0	$0	$0	$0	$0	$0	$0
Preferred Stock, Shares Outstanding	$0	$0	$0	$0	$0	$0	$0	$0